Nabriva Therapeutics plc (NBRVF)

Market Cap	646.00 -100.0%
Revenue (ttm)	29.56M -16.4%
Net Income	-55.05M
EPS	-17.90
Shares Out	3.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,913
Average Volume	1,265
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0002
52-Week Range	n/a
Beta	-6.10
RSI	57.47
Earnings Date	n/a

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company’s product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); XENLETA for the treatment of community-acquired bacterial pneumonia; and CONTEPO for the treatment of complicated urinary tract infections, including acute pyelonephritis. The company was formerly known as Nabriva Therapeutics ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 39
• Stock Exchange: OTCMKTS
• Ticker Symbol: NBRVF

Financial Performance

In 2022, Nabriva Therapeutics's revenue was $36.94 million, an increase of 27.82% compared to the previous year's $28.90 million. Losses were -$57.19 million, 15.6% more than in 2021.